Literature DB >> 32737742

Direct oral anticoagulants are effective and safe in the treatment of venous thromboembolism and atrial fibrillation in morbidly obese patients.

Mouhand F H Mohamed1, Hazem Elewa2, Mahmood Mubasher3, Mohammed Danjuma4,5.   

Abstract

Entities:  

Year:  2021        PMID： 32737742     DOI： 10.1007/s11239-020-02238-w

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN： 0929-5305            Impact factor:   2.300


× No keyword cloud information.
  3 in total

1.  Effectiveness and safety of rivaroxaban versus warfarin in obese nonvalvular atrial fibrillation patients: analysis of electronic health record data.

Authors:  Olivia S Costa; Jan Beyer-Westendorf; Veronica Ashton; Dejan Milentijevic; Kenneth Todd Moore; Thomas J Bunz; Craig I Coleman
Journal:  Curr Med Res Opin       Date:  2020-05-13       Impact factor: 2.580

Review 2.  Use of the direct oral anticoagulants in obese patients: guidance from the SSC of the ISTH.

Authors:  K Martin; J Beyer-Westendorf; B L Davidson; M V Huisman; P M Sandset; S Moll
Journal:  J Thromb Haemost       Date:  2016-04-27       Impact factor: 5.824

3.  Awareness campaigns of atrial fibrillation as an opportunity for early detection by pharmacists: an international cross-sectional study.

Authors:  Filipa Alves da Costa; Katerina Mala-Ladova; Vivian Lee; Salvador Tous; John Papastergiou; Dale Griffiths; Marie-Camille Chaumais; Kurt E Hersberger; Reka Viola; Ema Paulino; Trudie Lobban; Lis Neubeck; Ben Freedman; Sotiris Antoniou
Journal:  J Thromb Thrombolysis       Date:  2020-05       Impact factor: 2.300
  3 in total
  1 in total

1.  Effectiveness, safety, and healthcare costs associated with rivaroxaban versus warfarin among venous thromboembolism patients with obesity: a real-world study in the United States.

Authors:  Jeffrey S Berger; François Laliberté; Akshay Kharat; Dominique Lejeune; Kenneth Todd Moore; Young Jung; Patrick Lefebvre; Veronica Ashton
Journal:  J Thromb Thrombolysis       Date:  2022-05-13       Impact factor: 5.221
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.